How India Exports Dacarbazine to the World

Dacarbazine is approved in the United States for the treatment of metastatic malignant melanoma and Hodgkin's disease. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for dacarbazine, indicating a competitive generic market. As of March 2026, there are no active FDA import alerts specifically targeting dacarbazine from India, suggesting compliance with U.S. regulatory standards. However, Indian exporters must adhere to stringent FDA requirements, including Good Manufacturing Practices (GMP) and proper labeling, to maintain market access. Given the presence of 193 active Indian exporters, maintaining high compliance standards is crucial to avoid potential regulatory actions.

In the European Union, dacarbazine is authorized for use in treating metastatic malignant melanoma, Hodgkin's disease, and adult soft tissue sarcomas. The European Medicines Agency (EMA) oversees the approval and monitoring of such medicines. A notable case is the referral of Dacarbazine Faulding in August 2002, which underscores the importance of compliance with EMA regulations. Manufacturers exporting to the EU and UK must adhere to the EMA's Good Manufacturing Practice (GMP) guidelines, ensuring product quality and safety. Regular inspections and pharmacovigilance activities are conducted to maintain these standards.

Dacarbazine is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its significance in global health. This inclusion emphasizes the need for consistent quality and availability worldwide. Manufacturers are encouraged to meet international pharmacopoeia standards, such as those outlined in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure product efficacy and safety.

In India, dacarbazine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug requiring medical supervision. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including dacarbazine, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for dacarbazine have expired, leading to a competitive generic market. This has resulted in multiple manufacturers producing and exporting the drug, contributing to the 193 active Indian exporters. The absence of patent protection allows for increased accessibility and affordability of dacarbazine globally.

In June 2025, the NPPA revised the ceiling price for dacarbazine, reflecting changes in production costs and market dynamics. In September 2025, the EMA updated its list of nationally authorized medicinal products, including dacarbazine, to ensure up-to-date information on approved medicines. In December 2025, the WHO released the 21st edition of its Model List of Essential Medicines, reaffirming dacarbazine's inclusion and emphasizing its importance in cancer treatment protocols. These developments underscore the dynamic nature of the pharmaceutical industry and the need for continuous monitoring of regulatory changes.

Dacarbazine, an antineoplastic agent, is primarily manufactured in India, which has established itself as a significant producer of active pharmaceutical ingredients (APIs). However, the production of APIs like dacarbazine often relies on key starting materials (KSMs) and intermediates sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come exclusively from India. This heavy reliance on Chinese suppliers for critical raw materials introduces vulnerabilities into the supply chain.

In recent years, China's stringent environmental regulations have led to the shutdown of numerous chemical manufacturing facilities. For instance, over 145 API manufacturers in China ceased operations due to these regulations, causing significant disruptions in the supply of essential KSMs. Such disruptions have resulted in substantial price increases for key materials; for example, the cost of 5-Fluorocytosine, a KSM for oncology APIs, surged by 60%, while HMDS experienced a 484% price hike. These fluctuations underscore the risks associated with dependency on a concentrated geographic source for critical raw materials.

Our proprietary trade data indicates that the top five Indian exporters of dacarbazine account for 41.9% of the total export value, with VENUS REMEDIES LIMITED leading at an 11.9% share. This level of supplier concentration poses a risk, as any operational issues within these key companies could significantly impact the global supply of dacarbazine.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic manufacturing of critical APIs and reduce reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and 6-APA, which are vital for antibiotic production. While these initiatives are steps toward enhancing self-sufficiency, their impact on reducing supplier concentration in the dacarbazine supply chain remains to be seen.

Geopolitical tensions and shipping disruptions have further complicated the pharmaceutical supply chain. The Red Sea and the Strait of Hormuz are critical maritime routes for global trade, and any instability in these regions can delay shipments of raw materials and finished products. Additionally, escalating tensions between the U.S. and China have led to increased scrutiny and potential tariffs on pharmaceutical imports, affecting the cost and availability of APIs and KSMs.

Regulatory agencies have reported shortages of essential medications due to these supply chain challenges. For example, in November 2024, the European Medicines Agency (EMA) reported a shortage of fluorouracil, an antineoplastic agent, due to capacity issues at a manufacturing site in India. (ema.europa.eu) Such incidents highlight the fragility of the supply chain for critical medications like dacarbazine.

• Diversify Sourcing of KSMs and APIs: Establish alternative suppliers in different geographic regions to reduce dependency on a single country, particularly for critical raw materials.

• Enhance Domestic Manufacturing Capabilities: Invest in local production facilities for KSMs and APIs to strengthen supply chain resilience and reduce reliance on imports.

• Implement Robust Supplier Audits: Conduct regular assessments of suppliers' compliance with environmental and quality standards to anticipate potential disruptions.

• Develop Strategic Stockpiles: Maintain reserves of essential raw materials and finished products to buffer against supply chain interruptions.

• Monitor Geopolitical Developments: Stay informed about international relations and trade policies that may impact the pharmaceutical supply chain, allowing for proactive risk management.

RISK_LEVEL: MEDIUM